JP2023521604A5 - - Google Patents
Info
- Publication number
- JP2023521604A5 JP2023521604A5 JP2022559557A JP2022559557A JP2023521604A5 JP 2023521604 A5 JP2023521604 A5 JP 2023521604A5 JP 2022559557 A JP2022559557 A JP 2022559557A JP 2022559557 A JP2022559557 A JP 2022559557A JP 2023521604 A5 JP2023521604 A5 JP 2023521604A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- nucleotides
- mapt
- dsrna agent
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026032134A JP2026116278A (ja) | 2020-03-30 | 2026-03-02 | 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063002030P | 2020-03-30 | 2020-03-30 | |
| US63/002,030 | 2020-03-30 | ||
| US202163164467P | 2021-03-22 | 2021-03-22 | |
| US63/164,467 | 2021-03-22 | ||
| PCT/US2021/024858 WO2021202511A2 (en) | 2020-03-30 | 2021-03-30 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026032134A Division JP2026116278A (ja) | 2020-03-30 | 2026-03-02 | 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521604A JP2023521604A (ja) | 2023-05-25 |
| JP2023521604A5 true JP2023521604A5 (cg-RX-API-DMAC7.html) | 2024-04-10 |
Family
ID=77929772
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559557A Pending JP2023521604A (ja) | 2020-03-30 | 2021-03-30 | 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法 |
| JP2026032134A Pending JP2026116278A (ja) | 2020-03-30 | 2026-03-02 | 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026032134A Pending JP2026116278A (ja) | 2020-03-30 | 2026-03-02 | 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230203486A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4126230A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023521604A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230005194A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116234585A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021246024A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022019606A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3178304A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296851A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012293A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202143984A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021202511A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240067943A (ko) * | 2021-09-24 | 2024-05-17 | 알닐람 파마슈티칼스 인코포레이티드 | 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법 |
| US20250340872A1 (en) * | 2021-10-07 | 2025-11-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing tau expression |
| MX2024007056A (es) | 2021-12-13 | 2024-06-24 | Lilly Co Eli | Agentes de interferencia de arn de mapt. |
| US20250171777A1 (en) | 2022-02-11 | 2025-05-29 | Alnylam Pharmaceuticals, Inc. | Microtubule Associated Protein Tau (MAPT) iRNA Agent Compositions and Methods of Use Thereof |
| KR20240154674A (ko) * | 2022-03-16 | 2024-10-25 | 얀센 파마슈티카 엔브이 | MAPT siRNA 및 이의 용도 |
| WO2024145474A2 (en) * | 2022-12-29 | 2024-07-04 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2024201423A2 (en) * | 2023-03-30 | 2024-10-03 | Biorchestra Co., Ltd. | Microtubule-associated protein tau targeting sirnas and uses thereof |
| EP4698652A2 (en) * | 2023-04-20 | 2026-02-25 | Adarx Pharmaceuticals, Inc. | Mapt-modulating compositions and methods of use thereof |
| KR20260046111A (ko) * | 2023-08-01 | 2026-04-06 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | MAPT를 표적으로 하는 dsRNA 및 이의 의약적 용도 |
| EP4754256A1 (en) * | 2023-08-02 | 2026-06-10 | Consejo Nacional de Investigaciones Científicas Y Técnicas (CONICET) | Micrornas designed against the microtubule-associated protein tau for the treatment of tauopathies |
| KR20260085142A (ko) * | 2023-10-11 | 2026-06-08 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 미세소관 관련 단백질 tau(mapt)의 발현을 억제하기 위한 조성물 및 방법 |
| WO2025212467A1 (en) * | 2024-03-31 | 2025-10-09 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use |
| WO2025233849A2 (en) * | 2024-05-07 | 2025-11-13 | Janssen Pharmaceutica Nv | MAPT siRNA AND USES THEREOF |
| WO2026010722A1 (en) * | 2024-07-03 | 2026-01-08 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2026017176A1 (zh) * | 2024-07-19 | 2026-01-22 | 北京安龙生物医药有限公司 | 靶向微管相关蛋白Tau基因的寡核苷酸及其用途 |
| CN121780524A (zh) * | 2024-08-02 | 2026-04-03 | 北京尧景基因技术有限公司 | 抑制MAPT基因表达的siRNA及其缀合物和应用 |
| WO2026026982A1 (zh) * | 2024-08-02 | 2026-02-05 | 成都先衍生物技术有限公司 | 一种靶向MAPT基因表达的siRNA及其缀合物和用途 |
| US20260167963A1 (en) * | 2024-08-29 | 2026-06-18 | Synerk Inc. | Compounds, Compositions and Methods for Reducing MAPT (TAU) Expression |
| WO2026067655A1 (zh) * | 2024-09-26 | 2026-04-02 | 大睿生物医药科技(上海)有限公司 | 调控TAU表达的dsRNA分子 |
| WO2026085233A1 (en) * | 2024-10-16 | 2026-04-23 | Alnylam Pharmaceuticals, Inc. | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA FORMULATIONS AND METHODS OF USE THEREOF |
| WO2026090357A1 (en) * | 2024-10-24 | 2026-04-30 | Adarx Pharmaceuticals, Inc. | Mapt-modulating oligonucleotides for treating central nervous system diseases |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1948674A4 (en) * | 2005-11-02 | 2009-02-04 | Protiva Biotherapeutics Inc | MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF |
| GB0605337D0 (en) * | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| CA2866392C (en) * | 2012-03-30 | 2023-10-24 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| US9133461B2 (en) * | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| BR112015022156A2 (pt) * | 2013-03-14 | 2017-11-14 | Isis Pharmaceuticals Inc | composições e métodos para modular a expressão de tau |
| US9951330B2 (en) * | 2013-07-11 | 2018-04-24 | The Trustees Of Columbia University In The City Of New York | Micrornas that silence tau expression |
| TWI702046B (zh) * | 2013-07-19 | 2020-08-21 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| WO2015038892A1 (en) * | 2013-09-13 | 2015-03-19 | Moderna Therapeutics, Inc. | Polynucleotide compositions containing amino acids |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| CA2975525A1 (en) * | 2015-02-04 | 2016-08-11 | F. Hoffmann-La Roche Ag | Tau antisense oligomers and uses thereof |
| ES2820713T3 (es) * | 2015-03-25 | 2021-04-22 | Univ Degli Studi Di Trento | Terapia mediada por ARN interferente para enfermedades neurodegenerativas |
| CN117965536A (zh) * | 2015-07-22 | 2024-05-03 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| KR20250112919A (ko) * | 2015-12-21 | 2025-07-24 | 노파르티스 아게 | 타우 발현을 감소시키기 위한 조성물 및 방법 |
| JP7348185B2 (ja) * | 2017-12-21 | 2023-09-20 | アルニラム ファーマスーティカルズ インコーポレイテッド | キラル富化二本鎖rna剤 |
| TWI862501B (zh) * | 2018-07-03 | 2024-11-21 | 瑞士商赫孚孟拉羅股份公司 | 用於調制 Tau 表現之寡核苷酸 |
| CN115461085A (zh) * | 2020-02-07 | 2022-12-09 | 生物欧赛加有限责任公司 | miRNA-485抑制剂用于治疗tau蛋白病的用途 |
| JP2023518439A (ja) * | 2020-03-18 | 2023-05-01 | ユニバーシティー オブ マサチューセッツ | Mapt調節のためのオリゴヌクレオチド |
-
2021
- 2021-03-30 JP JP2022559557A patent/JP2023521604A/ja active Pending
- 2021-03-30 EP EP21779121.9A patent/EP4126230A4/en active Pending
- 2021-03-30 WO PCT/US2021/024858 patent/WO2021202511A2/en not_active Ceased
- 2021-03-30 TW TW110111671A patent/TW202143984A/zh unknown
- 2021-03-30 BR BR112022019606A patent/BR112022019606A2/pt unknown
- 2021-03-30 CA CA3178304A patent/CA3178304A1/en active Pending
- 2021-03-30 US US17/995,035 patent/US20230203486A1/en active Pending
- 2021-03-30 AU AU2021246024A patent/AU2021246024A1/en active Pending
- 2021-03-30 MX MX2022012293A patent/MX2022012293A/es unknown
- 2021-03-30 IL IL296851A patent/IL296851A/en unknown
- 2021-03-30 CN CN202180039190.6A patent/CN116234585A/zh active Pending
- 2021-03-30 KR KR1020227037984A patent/KR20230005194A/ko active Pending
-
2026
- 2026-03-02 JP JP2026032134A patent/JP2026116278A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7805386B2 (ja) | Lpa発現を阻害するための組成物及び方法 | |
| JP2024536811A5 (cg-RX-API-DMAC7.html) | ||
| JP6343308B2 (ja) | 筋緊張性ジストロフィー・プロテインキナーゼ(dmpk)発現の調整 | |
| JP6637442B2 (ja) | 補体b因子発現を調節するための組成物及び方法 | |
| CN110042098B (zh) | 用于调节hbv和ttr表达的组合物和方法 | |
| JP2022515193A5 (cg-RX-API-DMAC7.html) | ||
| TR201816256T4 (tr) | Bir süjede smn2 uç birleştirmesinin modülasyonu için bileşimler ve yöntemler. | |
| TWI924663B (zh) | 用於抑制PNPLA3表現之RNAi劑、其醫藥組成物及使用方法 | |
| JP2023523993A5 (cg-RX-API-DMAC7.html) | ||
| US20190016748A1 (en) | Compositions and methods for modulating angiopoietin-like 3 expression | |
| JP2013526860A (ja) | トランスサイレチン発現の調節 | |
| JP2017518045A (ja) | Pkk発現を調節するための組成物及び方法 | |
| US20240240187A1 (en) | Sirna targeting tmprss6 for the treatment of myeloproliferative disorders | |
| JP2023511434A5 (cg-RX-API-DMAC7.html) | ||
| WO2018057575A1 (en) | Myostatin irna compositions and methods of use thereof | |
| JP2024528503A5 (cg-RX-API-DMAC7.html) | ||
| IL294728A (en) | lrrk2 RNA material preparations and methods of using them | |
| JP2025507372A5 (cg-RX-API-DMAC7.html) | ||
| JP2024522068A5 (cg-RX-API-DMAC7.html) | ||
| JP2024509783A5 (cg-RX-API-DMAC7.html) | ||
| US11634715B2 (en) | Methods and compositions for treating bile duct paucity-associated conditions | |
| JP2024521907A5 (cg-RX-API-DMAC7.html) | ||
| US20220186229A1 (en) | Methods and compositions for inhibiting expression of cyp27a1 | |
| JP2025516321A5 (cg-RX-API-DMAC7.html) | ||
| RU2024111073A (ru) | КОМПОЗИЦИИ АГЕНТА иРНК ПРОТИВ АССОЦИИРОВАННОГО С МИКРОТРУБОЧКАМИ ТАУ-БЕЛКА (MAPT) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |